Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014

@article{NezCorts2014DislipidemiaAY,
  title={Dislipidemia aterog{\'e}nica y riesgo residual. Estado de la cuesti{\'o}n en 2014},
  author={Jes{\'u}s Mill{\'a}n N{\'u}{\~n}ez-Cort{\'e}s and Juan Pedro-Botet Montoya and Xavier Pint{\'o} Sala},
  journal={Cl{\'i}nica e Investigaci{\'o}n en Arteriosclerosis},
  year={2014},
  volume={26},
  pages={287-292}
}
11 Citations
Management of atherogenic dyslipidemia according to current treatment guidelines: DESPEGA study in real clinical practice
TLDR
Since adherence to clinical guidelines improves both the quality of care and health outcomes, greater adherence to and satisfaction with clinical guidelines for the management of AD may contribute to improvements in and optimization of themanagement of patients with AD in the Spanish health system.
Evaluation of Lipoprotein Profile and Residual Risk Three Years After Bariatric Surgery
TLDR
The type of surgical technique and the presurgery lipid profile predict variation after 3 years of BS are analyzed, including a group analysis of patients according to whether they had dyslipidemia and whether they were treated or untreated.
Psoriasis and Cardiovascular Risk: A Comprehensive Review
TLDR
The possible pathophysiological mechanisms that justify this association, the usefulness of the therapies frequently used in cardiovascular prevention and the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events are described.
Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
  • J. Ascaso, J. Millán, X. Pintó
  • Medicine
    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
  • 2017
...
1
2
...

References

SHOWING 1-10 OF 63 REFERENCES
Combination lipid therapy in type 2 diabetes.
TLDR
Drugs such as niacin that increase the level of HDL cholesterol remain a very promising option to reduce the residual vascular risk after the failure of fenofibrate, which pri­ marily lowers levels of triglycerides.
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
TLDR
This review will attempt to bring together information from recent cellular, biochemical, physiological, and molecular studies to provide an update of the understanding of both normal and abnormal TRLP metabolism and of the atherogenicity of TRLPs.
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
TLDR
The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual vascular risk among dyslipidaemic patients who are treated in accordance with current standards of care.
Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
TLDR
FENO-S lowered PP TG similarly in all participants compared with PL-S, but levels of atherogenic apoB48 particles were reduced only in individuals with increased fasting levels of TG, which may have implications for interpretation of the overall ACCORD Lipid trial.
Lipoprotein Management in Patients With Cardiometabolic Risk
TLDR
It is unclear whether lipoprotein parameters other than LDL or non-HDL cholesterol provide clinically significant additional prognostic information regarding CVD risk, yield more information about the effectiveness of therapy, or indicate more appropriate treatment targets.
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
TLDR
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
TLDR
Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib.
Safety considerations with fibrate therapy.
...
1
2
3
4
5
...